Intel stock extends gains after report of possible U.S. government stake
Murphy Canyon Acquisition Corp.’s stock (CDT) has reached a new 52-week low, with shares plummeting to $3.21. The micro-cap company, now valued at just $2.89 million, shows a "WEAK" overall financial health score according to InvestingPro analysis. This latest price level reflects a dramatic downturn for the company, which has seen its stock value erode by an astonishing 99.93% over the past year. Technical indicators, including RSI readings, suggest the stock is in oversold territory, though InvestingPro analysis indicates the shares remain overvalued despite the decline. Investors have watched with concern as the stock has steadily declined, culminating in this recent low point that underscores the challenges facing Murphy Canyon Acquisition Corp. in a volatile market. The company’s struggles are further evidenced by its negative earnings yield of -7.29% and concerning return on assets of -317%. The 1-year change data paints a stark picture of the company’s performance, signaling caution to shareholders and potential investors as they consider the company’s future prospects.
In other recent news, Conduit Pharmaceuticals Inc. has announced its compliance with Nasdaq’s listing standards, meeting the minimum bid price and stockholders’ equity requirements. This development ensures the company’s securities remain listed on the Nasdaq exchange, with a one-year Discretionary Panel Monitor in place to oversee continued compliance. Additionally, Conduit Pharmaceuticals’ board has approved a 1-for-15 reverse stock split, which took effect on May 19, 2025, consolidating shares and adjusting equity awards accordingly. The company has also made significant progress in its research and development efforts, particularly in preclinical lupus studies and the upcoming Phase IIa clinical trial for its autoimmune disease drug candidates. Collaborating with Charles River Laboratories Inc., Conduit is conducting studies on glucokinase inhibitors, with results expected in Q2 2025. Furthermore, Conduit has secured composition-of-matter patents for AZD1656 Cocrystals from the Japan Patent Office and IP Australia, with additional approvals anticipated. These recent developments reflect Conduit’s ongoing commitment to advancing its pipeline and maintaining its position on the Nasdaq exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.